The Global Oligonucleotide Synthesis Market was valued at USD 6.3 billion in 2021 and is expected to register a CAGR of 17.6% during the forecast period (2022 – 2026). The report studies the market scenario and its growth prospects during the forecast period. In addition, the report includes a detailed analysis of the leading competitors functioning in this market. In order to calculate the market size, the report considers the sales, value, volume, and exclude new installations, replacement, spares, shipments, aftermarket sales, retrofit, and services market.
The market research report on the Oligonucleotide Synthesis industry analyzes the overall estimates of all the segments and sub-segments of the market, on a global and regional scale. The report presents the historical data for the time period 2017-2021, revenue estimates from 2018-2022, and forecasts from 2021 till 2026. The report presents a detailed analysis of the market trends, market dynamics, leading competitors, technological innovations and inventions, key developments, lucrative opportunities, and future strategies. The market size is calculated on the basis of the financials generated through sales from the mentioned segments and sub-segments in this research study. The overall market has been analyzed using the top-down and bottom-up approaches for data validation and accuracy measures.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Some of the leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).
The Global Oligonucleotide Synthesis Market is defined by the presence of some of the leading competitors operating in the market, including the well-established players and new entrants, and the suppliers, vendors, and distributors. The key players are continuously focusing on expanding their geographic reach and broadening their customer base, in order to expand their product portfolio and come up with new advancements. The report also analyzes the development proposals and the feasibility of new investments. This report has been collated in order to provide guidance and direction to the companies and individuals interested in buying this research report.
The study categorizes the oligonucleotide synthesis market into the following segments and subsegments:
Oligonucleotide synthesis Market, by Product
- Oligonucleotide-based Drugs
- Synthesized Oligonucleotides
- By Product
- DNA Oligos
- RNA Oligos
- Other Synthesized Oligos
- By Type
- Customized Oligos
- Predesigned Oligos
Oligonucleotide synthesis Market, by Application
- Research Applications
- Other Research Applications
- Diagnostic Applications
Therapeutic Applications, By Type
- Antisense Oligonucleotide-based Therapies
- RNAi Oligonucleotide-based Therapies
- CpG Oligonucleotide-based Therapies
Therapeutic Applications, By Disease Type
- Neurological Disorders
- Infectious Diseases
- Other Diseases
Oligonucleotide synthesis Market, by End User
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- CROs and CMOs
- Academic Research Institutes
Request a Sample Copy of Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350
Some of the key geographies mentioned in this report include:
- North America (U.S and Canada and rest of North America)
- Europe (Germany, France, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
- LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.